"We are committed to providing these scientists--and the nearly 300 scientists who are already part of HHMI--with the freedom and flexibility they need in order to make lasting contributions to mankind," said Thomas R. Cech, HHMI's president. "We want and expect them to be daring."
HHMI chose the 43 scientists through a nationwide competition that began in 2004 when the Institute asked approximately 200 universities, medical schools, and institutes to nominate candidates who demonstrated exceptional promise within 4 to 10 years of their becoming independent scientists. More than 300 individuals were nominated.
Dr. Lowe is Deputy Director of the CSHL Cancer Center and is a world leader in the field of cancer biology. His research is focused on understanding programmed cell death and cellular senescence, on elucidating how cancer cells thwart these protective processes, and on developing improved cancer therapies. (For more about Lowe's research, see the links provided below.)
Dr. Hannon is a pioneer in the field of RNA interference. His research program seeks to understand the biology of the process and to harness the power of RNA interference for finding novel approaches to treating human cancer. (For more about Hannon's research, see the links provided below.)
Bruce Stillman, president of Cold Spring Harbor Laboratory, said, "The appointment of Hannon and Lowe continues the tradition of Cold Spring Harbor Laboratory scientists being selected as HHMI investigators. We are thrilled that the efforts of our researchers are being recognized in this way."